Phase I Study of SB751689 [ronacaleret] - Single and Multiple Oral Dose Study in Japanese Postmenopausal Women.
Latest Information Update: 04 Jul 2023
At a glance
- Drugs Ronacaleret (Primary)
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
Most Recent Events
- 14 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Nov 2007 New trial record.